Genetic diversity in the E6 and E7 gene of human papillomavirus type 16 among cervical cancer patients in Riau Province, Indonesia
##plugins.themes.bootstrap3.article.main##
Abstract
Cervical cancer mostly occurs due to persistent high-risk human papillomavirus (HPV), with type 16 being the most frequent. In Indonesia, cervical cancer ranks second in mortality, with a fatality rate of 57%. The E6 and E7 genes of HPV-16 play crucial roles in the virus’s oncogenic transformation, leading to cervical cancer. This study was conducted to determine the prevalence and genetic diversity of the E6 and E7 genes of HPV-16 in Riau Province, Indonesia. There were 37 HPV-positive samples analyzed using the MY09/11 primers. This was followed by the amplification of the E6 and E7 genes. Nineteen samples were detected as HPV-16, thirteen of which were coinfected with HPV-18. Seven E6 and E7 sequences were aligned compared with the reference sequence NC_001526.4. The most common nucleotide changes in the E6 gene, 7318A>G, was detected in 30.7% of samples, leading to an amino acid change from 65N>S. Three nucleotide changes were identified in the E7 gene of sample 89: two synonymous (7831T>C, 7837T>G) and one non-synonymous (7989A>G), resulting in an amino acid change of 29N>S. The most frequent E7 nucleotide change, 7708G>A, was found in 80% of samples. Phylogenetic analysis revealed that HPV-16 isolates from Riau have close kinship with the European lineage, with 57.1% (E6) and 85.7% (E7). In conclusion, the incidence of cervical cancer in Riau Province caused by HPV-16 is 52.8% and 7318A>G and 7708G>A are the most common genetic diversity. Furthermore, the majority of HPV-16 isolates in Riau Province show close kinship with the European lineage.
Downloads
##plugins.themes.bootstrap3.article.details##
Copyright (c) 2026 Maya Savira, Rachmadina Rachmadina, Azza Enggar Mahargyarani, Muhammad Zhafran Admiral, Donel S, Amru Sofian, Renady Reza Razali, Zidny Ilmiah, Analdi Farniga

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Li Z, Liu P, Yin A, Zhang B, Xu J, Chen Z, Zhang Z, Zhang Y, Wang S, Tang L, Kong B, Song K. Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: The urgent need to address inequalities in cervical cancer. Int J Cancer. 2025;157(2): 288–297. https://doi.org/10.1002/ijc.35369
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. https://doi.org/10.3322/caac.21834
Han L, Zhang B. Can prophylactic HPV vaccination reduce the recurrence of cervical lesions after surgery? Review and prospect. Infect Agent Cancer. 2023;18(1):66–77. https://doi.org/10.1186/s13027-023-00547-2
Nelson CW, Mirabello L. Human papillomavirus genomics: Understanding carcinogenicity. Tumour Virus Res. 2023;15(200258). https://doi.org/10.1016/j.tvr.2023.200258
Haręża DA, Wilczyński JR, Paradowska E. Human papillomaviruses as infectious agents in gynecological cancers―oncogenic properties of viral proteins. Int J Mol Sci. 2022;23(3):1818. https://doi.org/10.3390/ijms23031818
Ye Y, Jones T, Wang T, Zeng X, Liu Y, Zhao C. Comprehensive overview of genotype distribution and prevalence of human papillomavirus in cervical lesions. Gyn Obs Clin Med. 2024;4(1):e000005. https://doi.org/10.1136/gocm-2024-000005
González-Rodríguez JC, Cruz-Valdez A, Madrid-Marina V. Cervical cancer prevention by vaccination: Review. Front Oncol. 2024;14:1386167. https://doi.org/10.3389/fonc.2024.1386167
Vieira GV, Somera Dos Santos F, Lepique AP, da Fonseca CK, Innocentini LMAR, Braz-Silva PH, Quintana SM, Sales KU. Proteases and HPV-induced carcinogenesis. Cancers (Basel). 2022;14(13):3038. https://doi.org/10.3390/cancers14133038
Evande R, Rana A, Biswas-Fiss EE, Biswas SB. Protein–DNA interactions regulate human papillomavirus DNA replication, transcription, and oncogenesis. Int J Mol Sci. 2023;24(10):8493. https://doi.org/10.3390/ijms24108493
Munger K, White EA. What are the essential determinants of human papillomavirus carcinogenesis? mBio. 2024;15(11):e0046224. https://doi.org/10.1128/mbio.00462-24
Totaro ME, Gili JA, Liotta DJ, Schurr TG, Picconi MA, Badano I. Genetic variation in the E6 and E7 genes of human papillomavirus type 16 in northeastern Argentina. J Med Virol. 2022;94(2):745–51. https://doi.org/10.1002/jmv.27359
Li T, Yang Z, Zhang C, Wang S, Mei B. Genetic variation of E6 and E7 genes of human papillomavirus type 16 from central China. Virol J. 2023;20(1):217. https://doi.org/10.1186/s12985-023-02188-8
Akhatova A, Chan CK, Azizan A, Aimagambetova G. The efficacy of therapeutic DNA vaccines expressing the human papillomavirus E6 and E7 oncoproteins for treatment of cervical cancer: Systematic review. Vaccines (Basel). 2022;10(1):53. https://doi.org/10.3390/vaccines10010053
Othman AA, Goreal AA, Pity IS. Genotyping and phylogenetic analysis of human papillomaviruses in formalin fixed paraffin embedded sections from cervical lesions in Duhok-Iraq. Asian Pac J Cancer Prev. 2023;24(4):1313–9. https://doi.org/10.3390/vaccines10010053
Alsanea M, Alsaleh A, Obeid D, Alhadeq F, Alahideb B, Alhamlan F. Genetic variability in the E6, E7, and L1 genes of human papillomavirus types 16 and 18 among women in Saudi Arabia. Viruses. 2023;15(1):109. https://doi.org/10.3390/v15010109
Posada D, Crandall KA. Felsenstein phylogenetic likelihood. J Mol Evol. 2021;89(3):134–45. https://doi.org/10.1007/s00239-020-09982-w
Mahadani AK, Awasthi S, Sanyal G, Bhattacharjee P, Pippal S. Indel-K2P: A modified Kimura 2 parameters (K2P) model to incorporate insertion and deletion (Indel) information in phylogenetic analysis. Cyber-Physical Systems. 2022;8(1):32–44. https://doi.org/10.1080/23335777.2021.1879274
Wu P, Xiong H, Yang M, Li L, Wu P, Lazare C, Cao C, Gao P, Meng Y, Zhi W, Lin S, Hu J, Wei J, Ma D, Liu J, Yin P, Xing H. Co-infections of HPV16/18 with other high-risk HPV types and the risk of cervical carcinogenesis: A large population-based study. Gynecol Oncol. 2019;155(3):436–43. https://doi.org/10.1016/j.ygyno.2019.10.003
Savira M, Suhaimi D, Putra AE, Yusrawati Y, Lipoeto NI. Prevalence oncogenic human papillomavirus in cervical cancer patients in Riau Province Indonesia. Rep Biochem Mol Biol. 2022;10(4):573–9. https://doi.org/10.52547/rbmb.10.4.573
Bergqvist L, Kalliala I, Aro K, Auvinen E, Jakobsson M, Kiviharju M, Virtanen S, Dillner J, Nieminen P, Louvanto K. Distribution of hpv genotypes differs depending on behavioural factors among young women. Microorganisms. 2021;9(4):750. https://doi.org/10.3390/microorganisms9040750
Chen G, Zheng P, Gao L, Zhao J, Wang Y, Qin W. Prevalence and genotype distribution of human papillomavirus in women with cervical cancer or cervical intraepithelial neoplasia in Henan province, central China. J Med Virol. 2020;92(12):3743–9. https://doi.org/10.1002/jmv.25670
Ao M, Yao X, Zheng D, Gu X, Xi M. Risk of cervical intraepithelial neoplasia grade 3 or more diagnoses for human papillomavirus16/18-positive women by cytology and co-infection status. Infect Agent Cancer. 2023;18(1):57. https://doi.org/10.1186/s13027-023-00540-9
de Boer MA, Peters LA, Aziz MF, Siregar B, Cornain S, Vrede MA, Jordanova ES, Kolkman-Uljee S, Fleuren GJ. Human papillomavirus type 16 E6, E7, and L1 variants in cervical cancer in Indonesia, Suriname, and the Netherlands. Gynecol Oncol. 2004 Aug;94(2):488–94. https://doi.org/10.1016/j.ygyno.2004.05.037
Mahendra INB, Prayudi PKA, Dwija IBNP, Suwiyoga K. HPV16-E6/E7 Oncogene mutation and p53 expression among Indonesian women with cervical cancer. Asian Pac J Cancer Prev. 2022;23(8):2705–11. https://doi.org/10.31557/APJCP.2022.23.8.2705
Mahendra INB, Fani E, Budiana ING, Megadhana IW, Aryana MBD, Winata IGS. Correlation between E6 and E7 oncogene mutation human papilloma virus high risk type 16 with retinoblastoma protein expression in cervical cancer. Eur J Med Helathf Sci. 2022;4(6):65–70. https://doi.org/10.24018/ejmed.2022.4.6.1531
Liu Y, Denisov I, Gregory M, Sligar SG, Kincaid JR. Importance of asparagine 202 in manipulating active site structure and substrate preference for human CYP17A1. Biochem. 2022;61(7):583–94. https://doi.org/10.1021/acs.biochem.2c00023
Holeček M. Serine Metabolism in health and disease and as a conditionally essential amino acid. Nutrients. 2022 May 1;14(9):1987. https://doi.org/10.3390/nu14091987
Long T, Burk RD, Chan PKS, Chen Z. Non-human primate papillomavirus E6-mediated p53 degradation reveals ancient evolutionary adaptation of carcinogenic phenotype to host niche. PLoS Pathog. 2022;18(3):e1010444. https://doi.org/10.1371/journal.ppat.1010444
Li L, Dong X, Tang Y, Lao Z, Li X, Lei J, Wei G. Deciphering the mechanisms of HPV E6 mutations in the destabilization of E6/E6AP/p53 complex. Biophys J. 2022;121(9):1704–14. https://doi.org/10.1016/j.bpj.2022.03.030
King KM, Rajadhyaksha EV, Tobey IG, Van Doorslaer K. Synonymous nucleotide changes drive papillomavirus evolution. Tumour Virus Res. 2022;14:200248. https://doi.org/10.1016/j.tvr.2022.200248
Seal S, Dharmarajan G, Khan I. Evolution of pathogen tolerance and emerging infections: A missing experimental paradigm. Elife. 2021;10:E68874. https://doi.org/10.7554/eLife.68874
Dai MZ, Qiu Y, Di XH, Shi WW, Xu HH. Association of cervical carcinogenesis risk with HPV16 E6 and E7 variants in the Taizhou area, China. BMC Cancer. 2021;21(1):769. https://doi.org/10.1186/s12885-021-08531-y
Lou H, Boland JF, Li H, Burk R, Yeager M, Anderson SK, Wentzensen N, Schiffman M, Mirabello L, Dean M. HPV16 E7 Nucleotide variants found in cancer-free subjects affect E7 protein expression and transformation. Cancers (Basel). 2022;14(19):4895. https://doi.org/10.3390/cancers14194895
Asensio-Puig L, Alemany L, Pavón MA. A straightforward HPV16 lineage classification based on machine learning. Front Artif Intell. 2022;5:851841. https://doi.org/10.3389/frai.2022.851841
Santos GRBD, Cunha APA, Batista ZDS, Silva MACND, Figueiredo FV, Santos FRBD, Fraga EDC, Barros MC, Vidal FCB, Nascimento MDDSB. HPV 18 variants in women with cervical cancer in Northeast Brazil. Braz J Infect Dis. 2023;27(1):102734. https://doi.org/10.1016/j.bjid.2022.102734
Ahmed S, Vajeeha A, Idrees M, Hussain A, Munir R, Zaidi G, Zahid K, Ahmed R, Fatima Z, Rafique S, Achakzai NM. Genotypic distribution of human papillomavirus and phylogenetic analysis of E6 and E7 gene of HR-HPV variants isolated from Pakistani population. Medicine (United States). 2023;102(2):E32651. https://doi.org/10.1097/MD.0000000000032651
Burmeister CA, Khan SF, Schäfer G, Mbatani N, Adams T, Moodley J, Prince S. Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Res. 2022;13:200238. https://doi.org/10.1016/j.tvr.2022.200238
Ardhaoui M, Dekhil N, Bouslama Z, Bel Hadj Rhouma R, Fehri E, Ennaifer E, Guizani I. Tracing the evolutionary history of Tunisian HPV 16 and 18 across the genetic diversity in L1 gene. bioRxiv. 2024;580472. https://doi.org/10.1101/2024.02.15.580472
Wulandari SN, Raihan AU, Sasnita SD. The strategy of the riau islands province in facing challenges as a state border area. Proceedings of the International Conference Social - Humanities in Maritime and Border Area (SHIMBA 2023). Atlantis Press. 2023;110–4. https://doi.org/10.2991/978-2-38476-150-0_22
Hadami K, Saby C, Dakka N, Collin G, Attaleb M, Khyatti M, Filali-Maltouf A, Morjani H, El Mzibri M. Gene. 2021;791:145709. https://doi.org/10.1016/j.gene.2021.145709
Sun M, Gao L, Liu Y, Zhao Y, Wang X, Pan Y, Ning T, Cai H, Yang H, Zhai W, Ke Y. Whole genome sequencing and evolutionary analysis of human papillomavirus type 16 in Central China. PLoS One. 2012;7(5):e36577. https://doi.org/10.1371/journal.pone.0036577
Maya Savira
https://orcid.org/0000-0003-4663-030X
Analdi Farniga